Literature DB >> 33386676

Serum thrombospondin 2 is a novel predictor for the severity in the patients with NAFLD.

Takefumi Kimura1,2, Naoki Tanaka3,4, Naoyuki Fujimori1, Tomoo Yamazaki1, Takahito Katsuyama3, Yuichi Iwashita3, Jonathan Pham2, Satoru Joshita1, Sai P Pydi2, Takeji Umemura1,5.   

Abstract

AIM: Thrombospondins are a family of multidomain and secretory glycoproteins. Among them, thrombospondin 2 (TSP2) encoded by TSP2 gene has been reported to be involved in various functions such as collagen/fibrin formation, maintenance of normal blood vessel density and cell adhesion properties. Microarray analyses ranked TSP2 as one of the most highly up-regulated genes in the fibrotic liver in patients with non-alcoholic fatty liver disease (NAFLD). Since TSP2 possesses unique properties as a secretory protein, we hypothesized that hepatic TSP2 gene expression levels would be reflected in serum TSP2 levels. In this study, we examined the relationship between serum TSP2 concentrations and clinicopathological findings in NAFLD patients.
METHODS: One hundred and thirty NAFLD patients who had undergone liver biopsy between 2009 and 2015 were retrospectively enrolled. Serum samples were collected at the time of biopsy, and TSP2 was measured by enzyme immunoassays.
RESULTS: Serum TSP2 levels moderately correlated with ballooning (r = 0.56, P < .001) and fibrosis stage (r = 0.53, P < .001). The AUC values of TSP2 for predicting mild fibrosis (≧F1), moderate fibrosis (≧F2) and severe fibrosis (≧F3) were 0.73, 0.76 and 0.82 respectively. Additionally, NAFLD activity score (NAS) correlated best with TSP2 (r = 0.52, P < .001) compared to conventional NAFLD-related biomarkers, such as cytokeratin 18 M30, hyaluronic acid, type IV collagen 7S, APRI and FIB-4 index.
CONCLUSION: Serum TSP2 levels reflected hepatocyte ballooning, fibrosis and NAS in NAFLD patients. For clinical application of serum TSP2 as a predictor of NAFLD histological activity, additional validation and mechanistic investigations are required.
© 2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  MAFLD; NAFLD; NAS; NASH; ballooning; biomarker; fibrosis; thrombospondin 2

Year:  2021        PMID: 33386676     DOI: 10.1111/liv.14776

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  10 in total

1.  A predictive model for the diagnosis of non-alcoholic fatty liver disease based on an integrated machine learning method.

Authors:  Xuefeng Ma; Chao Yang; Kun Liang; Baokai Sun; Wenwen Jin; Lizhen Chen; Mengzhen Dong; Shousheng Liu; Yongning Xin; Likun Zhuang
Journal:  Am J Transl Res       Date:  2021-11-15       Impact factor: 4.060

Review 2.  Liver Fibrosis in Non-alcoholic Fatty Liver Disease: From Liver Biopsy to Non-invasive Biomarkers in Diagnosis and Treatment.

Authors:  Leen J M Heyens; Dana Busschots; Ger H Koek; Geert Robaeys; Sven Francque
Journal:  Front Med (Lausanne)       Date:  2021-04-14

3.  Transplantation of umbilical cord-derived mesenchymal stem cells promotes the recovery of thin endometrium in rats.

Authors:  Lu Zhang; Ying Li; Yi-Chao Dong; Chun-Yi Guan; Shi Tian; Xiao-Dan Lv; Jian-Hui Li; Xing Su; Hong-Fei Xia; Xu Ma
Journal:  Sci Rep       Date:  2022-01-10       Impact factor: 4.996

Review 4.  Role of G Protein-Coupled Receptors in Hepatic Stellate Cells and Approaches to Anti-Fibrotic Treatment of Non-Alcoholic Fatty Liver Disease.

Authors:  Takefumi Kimura; Simran Singh; Naoki Tanaka; Takeji Umemura
Journal:  Front Endocrinol (Lausanne)       Date:  2021-12-06       Impact factor: 5.555

5.  Thrombospondin 2 Promotes IL-6 Production in Osteoarthritis Synovial Fibroblasts via the PI3K/AKT/NF-κB Pathway.

Authors:  Chun-Han Hou; Chih-Hsin Tang; Po-Chun Chen; Ju-Fang Liu
Journal:  J Inflamm Res       Date:  2021-11-13

Review 6.  Diagnostic and Prognostic Roles of Thrombospondin-2 in Digestive System Cancers.

Authors:  Feiqiong Gao; Wenyi Chen; Tingxiao Zhao; Jiong Yu; Xudong Feng; Lan Wang; Tianan Jiang; Hongcui Cao
Journal:  Biomed Res Int       Date:  2022-07-14       Impact factor: 3.246

7.  Screening of the Key Genes and Signalling Pathways for Diabetic Nephropathy Using Bioinformatics Analysis.

Authors:  Zukai Li; Junxia Feng; Jinting Zhong; Meizhi Lu; Xuejuan Gao; Yunfang Zhang
Journal:  Front Endocrinol (Lausanne)       Date:  2022-07-12       Impact factor: 6.055

8.  High frequency and long persistency of ballooning hepatocyte were associated with glucose intolerance in patients with severe obesity.

Authors:  Keisuke Kakisaka; Akira Sasaki; Akira Umemura; Haruka Nikai; Yuji Suzuki; Masao Nishiya; Tamotsu Sugai; Hiroyuki Nitta; Yasuhiro Takikawa
Journal:  Sci Rep       Date:  2021-07-28       Impact factor: 4.379

9.  Molecular characterization and cell type composition deconvolution of fibrosis in NAFLD.

Authors:  Lorena Pantano; George Agyapong; Yang Shen; Zhu Zhuo; Francesc Fernandez-Albert; Werner Rust; Dagmar Knebel; Jon Hill; Carine M Boustany-Kari; Julia F Doerner; Jörg F Rippmann; Raymond T Chung; Shannan J Ho Sui; Eric Simon; Kathleen E Corey
Journal:  Sci Rep       Date:  2021-09-10       Impact factor: 4.379

10.  Transcriptomics Identify Thrombospondin-2 as a Biomarker for NASH and Advanced Liver Fibrosis.

Authors:  Kazuhiro Kozumi; Takahiro Kodama; Hiroki Murai; Sadatsugu Sakane; Olivier Govaere; Simon Cockell; Daisuke Motooka; Naruyasu Kakita; Yukinori Yamada; Yasuteru Kondo; Yuki Tahata; Ryoko Yamada; Hayato Hikita; Ryotaro Sakamori; Yoshihiro Kamada; Ann K Daly; Quentin M Anstee; Tomohide Tatsumi; Eiichi Morii; Tetsuo Takehara
Journal:  Hepatology       Date:  2021-08-21       Impact factor: 17.425

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.